HYPD

Hyperion DeFi is not a pharmaceutical company in any investable sense — it is the former Eyenovia, a chronically loss-making ophthalmic-device shell (FY2025 revenue just $813K against a -$45.3M net loss, a -5,743% operating margin, and a -$241M accumulated deficit) that has bolted on a crypto-treasury strategy. By management's own words in the MD&A, the company exists to 'provide our shareholders with simplified exposure to the Hyperliquid ecosystem,' having used ~$50M of private-placement proceeds to 'build a reserve of HYPE.' The equity is therefore a leveraged proxy on one early-stage, extremely volatile digital asset — not a durable operating business. The Optejet device remains pre-revenue after years, and R&D was slashed 86.8% to $1.9M, signaling the legacy business is being wound down, not built.

The filing's own Risk Factors are damning and specific: HYPE 'launched in November 2024,' has a 'limited operating history,' and is 'subject to extreme price volatility.' Worse, roughly '238 million HYPE tokens or more' are held by core contributors whose multi-year unlocks 'began on November 29, 2025' — a structural supply overhang that could 'depress the price of our common stock' precisely as the treasury's mark-to-market value falls. A single-asset treasury tied to a token that could 'severely decline' is the definition of unknowable, concentrated risk.